Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 563Neoplasms 462Carcinoma, Non-Small-Cell Lung 422Prostatic Neoplasms 344Colorectal Neoplasms 325Lung Neoplasms 269Multiple Myeloma 235Neoplasm Metastasis 197Pancreatic Neoplasms 189Leukemia, Myeloid, Acute 187Ovarian Neoplasms 182Melanoma 153Squamous Cell Carcinoma of Head and Neck 143Head and Neck Neoplasms 121Recurrence 119Carcinoma, Renal Cell 119Carcinoma, Hepatocellular 119Stomach Neoplasms 116Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Glioblastoma 114Endometrial Neoplasms 114Lymphoma 113Brain Neoplasms 111Lymphoma, Non-Hodgkin 108Uterine Cervical Neoplasms 101Triple Negative Breast Neoplasms 99Hematologic Neoplasms 98Urinary Bladder Neoplasms 97Glioma 91Leukemia, Lymphocytic, Chronic, B-Cell 88

Interventions

Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lethal Congenital Contracture Syndrome 2 × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡